Abstract:Highlights • LUZP1 expression was progressively increased in hearts after TAC surgery. • Cardiac-specific LUZP1 deficiency aggravated pressure overload-induced cardiac hypertrophy. • Cardiac-specific LUZP1 overexpression attenuated pressure overload-induced cardiac hypertrophy. • Stat3 pathway was a downstream target of LUZP1 in regulating pathological cardiac hypertrophy. • LUZP1 elevated SHP1 expression to inactivate Stat3 pathway. Introduction Cardiac hypertrophy is an important contributor of heart failure, and the mechanisms remain unclear. Leucine zipper protein 1 (LUZP1) is essential for the development and function of cardiovascular system; however, its role in cardiac hypertrophy is elusive. Objectives This study aims to investigate the molecular basis of LUZP1 in cardiac hypertrophy and to provide a rational therapeutic approach. Methods Cardiac-specific Luzp1 knockout (cKO) and transgenic mice were established, and transverse aortic constriction (TAC) was used to induce pressure overload-induced cardiac hypertrophy. The possible molecular basis of LUZP1 in regulating cardiac hypertrophy was determined by transcriptome analysis. Neonatal rat cardiomyocytes were cultured to elucidate the role and mechanism of LUZP1 in vitro. Results LUZP1 expression was progressively increased in hypertrophic hearts after TAC surgery. Gain- and loss-of-function methods revealed that cardiac-specific LUZP1 deficiency aggravated, while cardiac-specific LUZP1 overexpression attenuated pressure overload-elicited hypertrophic growth and cardiac dysfunction in vivo and in vitro. Mechanistically, the transcriptome data identified Stat3 pathway as a key downstream target of LUZP1 in regulating pathological cardiac hypertrophy. Cardiac-specific Stat3 deletion abolished the pro-hypertrophic role in LUZP1 cKO mice after TAC surgery. Further findings suggested that LUZP1 elevated the expression of Src homology region 2 domain-containing phosphatase 1 (SHP1) to inactivate Stat3 pathway, and SHP1 silence blocked the anti-hypertrophic effects of LUZP1 in vivo and in vitro. Conclusion We demonstrate that LUZP1 attenuates pressure overload-induced cardiac hypertrophy through inhibiting Stat3 signaling, and targeting LUZP1 may develop novel approaches to treat pathological cardiac hypertrophy. Graphical abstract LUZP1 expression was increased in pressure overload-induced cardiac hypertrophy in postnatal mice. By constructing cardiac-specific Luzp1 knockout and transgenic mice, we demonstrated that cardiac-specific LUZP1 deficiency aggravated, while cardiac-specific LUZP1 overexpression attenuated pressure overload-induced cardiac hypertrophy and dysfunction. Mechanistically, LUZP1 elevated SHP1 expression to inactivate Stat3 pathway, thereby preventing pathological cardiac hypertrophy. Accordingly, SHP1 silence blocked the anti-hypertrophic effects of LUZP1 in vivo and in vitro. Download : Download high-res image (150KB) Download : Download full-size image

SENP1 Protects Against Pressure Overload-Induced Cardiac Remodeling and Dysfunction Via Inhibiting STAT3 Signaling

Cardiomyocytes Deficiency of SENP1 Promotes Myocardial Fibrosis Via Paracrine Action

Endothelial S1pr1 Regulates Pressure Overload‐induced Cardiac Remodelling Through AKT‐eNOS Pathway

Signal Transducer and Transcriptional Activation 1 Protects Against Pressure Overload‐induced Cardiac Hypertrophy

Smad Nuclear Interacting Protein 1 Acts as a Protective Regulator of Pressure Overload-Induced Pathological Cardiac Hypertrophy.

Senp1 Protects Against Myocardial Ischaemia/Reperfusion Injury Via A Hif1 Alpha-Dependent Pathway

SENP1‐Mediated HSP90ab1 DeSUMOylation in Cardiomyocytes Prevents Myocardial Fibrosis by Paracrine Signaling

Induction of SENP1 in myocardium contributes to abnormities of mitochondria and cardiomyopathy.

Leucine zipper protein 1 attenuates pressure overload-induced cardiac hypertrophy through inhibiting Stat3 signaling

Activation of SIRT1 by Resveratrol Alleviates Pressure Overload-Induced Cardiac Hypertrophy via Suppression of TGF-β1 Signaling

Knockout of AMPK alpha 2 Blocked the Protection of Sestrin2 Overexpression Against Cardiac Hypertrophy Induced by Pressure Overload

Knockout of AMPKα2 Blocked the Protection of Sestrin2 Overexpression Against Cardiac Hypertrophy Induced by Pressure Overload

Angiotensin-Converting Enzyme 3 (Ace3) Protects Against Pressure Overload-Induced Cardiac Hypertrophy

SH2B1 is critical for the regulation of cardiac remodelling in response to pressure overload.

Exacerbating Pressure Overload–Induced Cardiac Hypertrophy

Sorting Nexin 3 Induces Heart Failure Via Promoting Retromer-Dependent Nuclear Trafficking of STAT3

LCZ696 Ameliorates Oxidative Stress and Pressure Overload-Induced Pathological Cardiac Remodeling by Regulating the Sirt3/MnSOD Pathway

STAT3 Suppression is Involved in the Protective Effect of SIRT6 Against Cardiomyocyte Hypertrophy.

Redox-sensitive Enzyme SENP3 Mediates Vascular Remodeling Via De-Sumoylation of Β-Catenin and Regulation of Its Stability

S-nitrosylation of C-Jun N-terminal Kinase Mediates Pressure Overload-Induced Cardiac Dysfunction and Fibrosis

SENP3 protects H9C2 cells from apoptosis triggered by H/R via STAT3 pathway.